GlassScriptPhysician profile
Javier Antonio Castillo
NPI 1568621084
$40,944.51
in general payments reported to CMS, 2019-2025
19 companies · $4,081 in 2025
The $4,081 reported for 2025 was more than what 89% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,812 · 2020: $96.03 · 2021: $428 · 2022: $8,524 · 2023: $18K · 2024: $3,127 · 2025: $4,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $4,080 · Food and Beverage: $2,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,992.50 |
| Travel and Lodging | $4,080.20 |
| Food and Beverage | $2,011.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $38,797.34 | 2019-2025 | Greenlight Xps, Spaceoar Vue System - 10ml, Ams 700 |
| Medtronic, INC. | $754.59 | 2019-2025 | Interstim, Signia, Tri-Ad |
| Janssen Pharmaceuticals, INC | $250.37 | 2021-2025 | Erleada, Talvey, Darzalex |
| Merck Sharp & Dohme LLC | $193.05 | 2023-2025 | Keytruda |
| Bard Peripheral Vascular, INC. | $178.21 | 2022 | |
| Ferring Pharmaceuticals INC. | $178.08 | 2019-2025 | Adstiladrin |
| E.R. Squibb & Sons, L.L.C. | $101.11 | 2024 | Opdivo |
| Teleflex LLC | $91.51 | 2021-2023 | Urolift |
| Becton, Dickinson and Company | $64.85 | 2023-2025 | Aptra, Lutonix Drug Coated Balloon |
| Verity Pharmaceuticals INC. | $61.94 | 2021-2023 | Trelstar |
| Janssen Biotech, INC. | $61.00 | 2019 | |
| Tolmar, INC. | $53.81 | 2023-2025 | Rubraca, Eligard |
| Siemens Medical Solutions USA, INC. | $33.30 | 2019 | |
| Allergan, INC. | $30.87 | 2019-2020 | |
| Neotract INC. | $28.00 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $19.14 | 2024 | |
| Pbg Puerto Rico LLC | $18.19 | 2021 | |
| Pharmaand Gmbh | $15.29 | 2025 | Rubraca |
| Pfizer INC. | $13.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.